2026 Step Therapy Criteria — select CNS agents (antidepressants, antipsychotics, dextromethorphan/bupropion, trazodone)
Customize your policy alerts
Sign up for all meridian policy alerts
Know when meridian releases new policies or updates existing guidance.
Monitor payer policy activity
Defines Meridian Health Plan step therapy requirements for selected antidepressants, oral antipsychotics, dextromethorphan/bupropion products (Auvelity/Exxua), and trazodone; applies to prior authorization and coverage decisions for affected pharmacy products under Meridian's 2026 policy.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.